Ki Hyeong Lee

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6142744/publications.pdf

Version: 2024-02-01

121	21,621	76196	26548
papers	citations	40 h-index	107 g-index

121	121	121	14871
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. Journal of Thoracic Oncology, 2022, 17, 289-308.	0.5	173
2	Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2022, 40, 1301-1311.	0.8	445
3	Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Patients With Advanced Nonâ€“Squamous Nonâ€“Small Cell Lung Cancer. Clinical Lung Cancer, 2022, 23, 214-225.	1.1	14
4	A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology, 2022, 17, 558-567.	0.5	43
5	Abstract P1-16-01: Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer: A randomized, open-label, multicenter, phase II trial (KCSG-BR15-17). Cancer Research, 2022, 82, P1-16-01-P1-16-01.	0.4	0
6	Diagnostic Value of Ascitic Tumor Markers for Gastric Cancer-associated Malignant Ascites. The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2022, 22, 38-49.	0.1	3
7	Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncology, The, 2022, 23, 781-792.	5.1	150
8	Association of depth of target lesion response to brigatinib with outcomes in patients with ALK inhibitor-naive ALK+ NSCLC in ALTA-1L.. Journal of Clinical Oncology, 2022, 40, 9072-9072.	0.8	0
9	Two-year update from KEYNOTE-799: Pembrolizumab plus concurrent chemoradiation therapy (cCRT) for unresectable, locally advanced, stage III NSCLC.. Journal of Clinical Oncology, 2022, 40, 8508-8508.	0.8	16
10	A randomized phase II study comparing erlotinib with or without bevacizumab in patients with advanced nonâ€“small cell lung cancer (NSCLC) with EGFR mutation.. Journal of Clinical Oncology, 2022, 40, 9107-9107.	0.8	0
11	Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Nonâ€“small Cell Lung Cancer. Clinical Cancer Research, 2021, 27, 992-1002.	3.2	36
12	The patientâ€™s perspective on treatment with dacomitinib: patient-reported outcomes from the Phase III trial ARCHER 1050. Future Oncology, 2021, 17, 783-794.	1.1	0
13	TOX-expressing terminally exhausted tumor-infiltrating CD8+ T cells are reinvigorated by co-blockade of PD-1 and TIGIT in bladder cancer. Cancer Letters, 2021, 499, 137-147.	3.2	42
14	Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. Drugs, 2021, 81, 257-266.	4.9	57
15	Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050). Lung Cancer, 2021, 154, 176-185.	0.9	18
16	KEYNOTE-799: Phase 2 trial of pembrolizumab plus platinum chemotherapy and radiotherapy for unresectable, locally advanced, stage 3 NSCLC.. Journal of Clinical Oncology, 2021, 39, 8512-8512.	0.8	13
17	Comparison of Bleeding, Hematoma, Pain, and Discomfort After Bone Marrow Examination With or Without Sandbag Compression. Asian Nursing Research, 2021, 15, 150-156.	0.7	0
18	Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Nonâ€“Small-Cell Lung Cancer (MYSTIC). Clinical Lung Cancer, 2021, 22, 301-312.e8.	1.1	10

#	Article	IF	Citations
19	Amivantamab in EGFR Exon 20 Insertionâ€“Mutated Nonâ€“Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. Journal of Clinical Oncology, 2021, 39, 3391-3402.	0.8	320
20	Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies. JTO Clinical and Research Reports, 2021, 2, 100224.	0.6	6
21	Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors. JTO Clinical and Research Reports, 2021, 2, 100206.	0.6	3
22	E-Cadherin and Angiopoietin-2 as Potential Biomarkers for Colorectal Cancer With Peritoneal Carcinomatosis. Anticancer Research, 2021, 41, 4497-4504.	0.5	5
23	Brigatinib Versus Crizotinib in ALK Inhibitorâ€“Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. Journal of Thoracic Oncology, 2021, 16, 2091-2108.	0.5	156
24	Histologic Changes in Non-Small Cell Lung Cancer Under Various Treatments: A Comparison of Histology and Mutation Status in Serial Samples. Cancer Research and Treatment, 2021, , .	1.3	5
25	Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Nonâ€“Small Cell Lung Cancer. JAMA Oncology, 2021, 7, 1351.	3.4	113
26	Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLCâ€”Update from PACIFIC. Journal of Thoracic Oncology, 2020, 15, 288-293.	0.5	328
27	Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. New England Journal of Medicine, 2020, 382, 41-50.	13.9	1,725
28	Brigatinib Versus Crizotinib in Advanced ALK Inhibitorâ€“Naive ALK-Positive Nonâ€“Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. Journal of Clinical Oncology, 2020, 38, 3592-3603.	0.8	224
29	18F-fluorodeoxyglucose positron emission tomography/computed tomography findings in descending necrotizing mediastinitis and cervical vertebral osteomyelitis in a cancer patient. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Overlock		
30	Differences in diagnosis, treatment, and survival rate of acute myeloid leukemia with or without disabilities: A national cohort study in the Republic of Korea. Cancer Medicine, 2020, 9, 5335-5344.	1.3	7
31	Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-Î² and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. Journal of Thoracic Oncology, 2020, 15, 1210-1222.	0.5	119
32	Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Nonâ€“Small Cell Lung Cancer. JAMA Oncology, 2020, 6, 661.	3.4	446
33	Phase II study of pembrolizumab (pembro) plus platinum doublet chemotherapy and radiotherapy as first-line therapy for unresectable, locally advanced stage III NSCLC: KEYNOTE-799.. Journal of Clinical Oncology, 2020, 38, 9008-9008.	0.8	15
34	Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1.. Journal of Clinical Oncology, 2020, 38, 9500-9500.	0.8	42
35	Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).. Journal of Clinical Oncology, 2020, 38, 9503-9503.	0.8	179
36	Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2020, 38, 9512-9512.	0.8	54

#	Article	IF	Citations
37	Two-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-Î² and PD-L1, for second-line (2L) treatment of non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2020, 38, 9558-9558.	0.8	7
38	ctDNA resistance landscape of lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI).. Journal of Clinical Oncology, 2020, 38, 9601-9601.	0.8	1
39	The Effect of Disability on the Diagnosis and Treatment of Multiple Myeloma in Korea: A National Cohort Study. Cancer Research and Treatment, 2020, 52, 1-9.	1.3	9
40	Real World Experience of Nivolumab in Non-Small Cell Lung Cancer in Korea. Cancer Research and Treatment, 2020, 52, 1112-1119.	1.3	10
41	A phase III, open-label, randomized study of atezolizumab in combination with carboplatin + paclitaxel + bevacizumab compared with pemetrexed + cisplatin or carboplatin with stage IV non-squamous non-small cell lung cancer (NSCLC) with activating EGFR mutation or ALK translocation (ATLAS Trial).. Journal of Clinical Oncology, 2020, 38, TPS9636-TPS9636.	0.8	2
42	363â€…Vactosertib and durvalumab as second or later line treatment for PD-L1 positive non-small cell lung cancer: interim result. , 2020, , .		2
43	Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer. Future Oncology, 2019, 15, 2795-2805.	1.1	27
44	Pseudoprogression presenting as intestinal perforation in nonâ€‘small cell lung cancer treated with antiâ€‘PDâ€‘1: A case report. Molecular and Clinical Oncology, 2019, 11, 132-134.	0.4	9
45	Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial. Lung Cancer, 2019, 135, 66-72.	0.9	22
46	Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1â€“2 study. Lancet Oncology, The, 2019, 20, 1681-1690.	5.1	92
47	Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study. Lancet Oncology, The, 2019, 20, 1670-1680.	5.1	125
48	Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 1655-1669.	5.1	418
49	A Case of Acquired Amegakaryocytic Thrombocytopenia with Anti-c-mpl Autoantibody: Comparison with Idiopathic Thrombocytopenic Purpura. Acta Haematologica, 2019, 142, 239-243.	0.7	3
50	Quality of life outcomes including neuropathyâ€‐associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as firstâ€‐line chemotherapy for HER2â€‐negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	3.7	5
51	Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced nonâ€“small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. European Journal of Cancer, 2019, 116, 137-147.	1.3	167
52	First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. Lung Cancer, 2019, 133, 10-19.	0.9	25
53	Molecular alterations and poziotinib efficacy, a panâ€HER inhibitor, in human epidermal growth factor receptor 2 (HER2)â€positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2â€positive breast cancer patients. International Journal of Cancer, 2019, 145, 1669-1678.	2.3	14
54	First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1569-1579.	1.2	31

#	Article	IF	Citations
55	Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset. Journal of Thoracic Oncology, 2019, 14, 99-106.	0.5	82
56	JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2019, 37, 9009-9009.	0.8	74
57	Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) Â± tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC.. Journal of Clinical Oncology, 2019, 37, 9016-9016.	0.8	20
58	Patient-reported outcomes (PROs) with first-line durvalumab (D) Â± tremelimumab (T) versus chemotherapy (CT) in metastatic NSCLC: Results from MYSTIC.. Journal of Clinical Oncology, 2019, 37, 9048-9048.	0.8	2
59	Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-NaÂ¨ve Korean Patients with Extensive-Disease Small Cell Lung Cancer. Cancer Research and Treatment, 2019, 51, 119-127.	1.3	23
60	A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13. Cancer Research and Treatment, 2019, 51, 718-726.	1.3	10
61	Exosomal miR-181b-5p Downregulation in Ascites Serves as a Potential Diagnostic Biomarker for Gastric Cancer-associated Malignant Ascites. Journal of Gastric Cancer, 2019, 19, 301.	0.9	24
62	Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07). British Journal of Cancer, 2018, 118, 648-653.	2.9	31
63	Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials. Clinical Lung Cancer, 2018, 19, e465-e479.	1.1	56
64	Osimertinib in UntreatedEGFR-Mutated Advanced Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 378, 113-125.	13.9	3,530
65	Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Nonâ€“Small-Cell Lung Cancer and EGFR-Activating Mutations. Journal of Clinical Oncology, 2018, 36, 2244-2250.	0.8	361
66	CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 3290-3297.	0.8	515
67	Diagnostic benefits of the combined use of liquid-based cytology, cell block, and carcinoembryonic antigen immunocytochemistry in malignant pleural effusion. Journal of Thoracic Disease, 2018, 10, 4931-4939.	0.6	29
68	EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors. Cancer Research and Treatment, 2018, 50, 908-916.	1.3	32
69	Long-term Survival after Repeated Local Therapy and Salvage Chemotherapy for Recurrent Metastases from Gastric Cancer: a Case Report and Literature Review. Journal of Gastric Cancer, 2018, 18, 305.	0.9	0
70	Brigatinib versus Crizotinib in ALK-Positive Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 379, 2027-2039.	13.9	691
71	Pembrolizumab plus Chemotherapy for Squamous Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 379, 2040-2051.	13.9	2,676
72	Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy. Lung Cancer, 2018, 122, 234-242.	0.9	22

#	Article	IF	Citations
73	A phase II trial of the panâ€HER inhibitor poziotinib, in patients with HER2â€positive metastatic breast cancer who had received at least two prior HER2â€directed regimens: results of the NOV120101â€203 trial. International Journal of Cancer, 2018, 143, 3240-3247.	2.3	46
74	Feasibility and accessibility of electronic patient-reported outcome measures using a smartphone during routine chemotherapy: a pilot study. Supportive Care in Cancer, 2018, 26, 3721-3728.	1.0	21
75	Do health literacy and selfâ€care behaviours affect quality of life in older persons with lung cancer receiving chemotherapy?. International Journal of Nursing Practice, 2018, 24, e12691.	0.8	11
76	Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma. JAMA Oncology, 2018, 4, 1189.	3.4	53
77	Dacomitinib (daco) versus gefitinib (gef) for first-line treatment of advanced NSCLC (ARCHER 1050): Final overall survival (OS) analysis.. Journal of Clinical Oncology, 2018, 36, 9004-9004.	0.8	9
78	Results from a second-line (2L) NSCLC cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF-Î² and PD-L1.. Journal of Clinical Oncology, 2018, 36, 9017-9017.	0.8	10
79	YH25448, a 3rd generation EGFR-TKI, in patients with EGFR-TKI-resistant NSCLC: Phase I/II study results.. Journal of Clinical Oncology, 2018, 36, 9033-9033.	0.8	2
80	Efficacy and safety results of ramucirumab in combination with osimertinib in advanced T790M-positive EGFR-mutant NSCLC.. Journal of Clinical Oncology, 2018, 36, 9053-9053.	0.8	4
81	Role of HER2 copy number amplification and PI3K pathway as a biomarker for patients with HER2+ MBC treating with Poziotinib, pan-HER TKI.. Journal of Clinical Oncology, 2018, 36, e13009-e13009.	0.8	1
82	Prevalence of and factors associated with anxiety and depression in Korean patients with newly diagnosed advanced gastrointestinal cancer. Korean Journal of Internal Medicine, 2018, 33, 585-594.	0.7	28
83	Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01). Journal of Pathology and Translational Medicine, 2018, 52, 148-156.	0.4	15
84	Quality of life(QoL) outcomes including neuropathy associated scale (FACT-T) from a phase II, multicenter, randomized trial of eribulin plus gemcitabine(EG) versus paclitaxel plus gemcitabine(PG) as first-line chemotherapy for human epidermal growth factor receptor 2 (HER2)- negative metastatic breast cancer(MBC): Korean Cancer Study Group trial (KCSG BR13-11).. Journal of Clinical Oncology, 2018, 36, 10117-10117.	0.8	0
85	Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14â€01). Cancer, 2017, 123, 1958-1964.	2.0	44
86	Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2017, 18, 1454-1466.	5.1	877
87	Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer. European Journal of Cancer, 2017, 86, 385-393.	1.3	23
88	Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2017, 35, 3449-3457.	0.8	311
89	Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Nonâ€“Small-Cell Lung Cancer Harboring ROS1 Rearrangement. Journal of Clinical Oncology, 2017, 35, 2613-2618.	0.8	260
90	A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01). Oncotarget, 2017, 8, 15943-15951.	0.8	11

#	Article	IF	Citations
91	Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial.. Journal of Clinical Oncology, 2017, 35, LBA9007-LBA9007.	0.8	3
92	PEARLY: A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo)adjuvant therapy in patients with early triple-negative breast cancer.. Journal of Clinical Oncology, 2017, 35, TPS587-TPS587.	0.8	6
93	Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial.. Journal of Clinical Oncology, 2017, 35, LBA9007-LBA9007.	0.8	21
94	A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (<i>EGFR</i>)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFRâ€“Tyrosine Kinase Inhibitors. Cancer Research and Treatment, 2017, 49, 10-19.	1.3	35
95	Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer. Cancer Research and Treatment, 2017, 49, 1001-1011.	1.3	43
96	Phase II study of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) in Korea.. Journal of Clinical Oncology, 2017, 35, 92-92.	0.8	0
97	A phase II, multicenter, randomized trial of eribulin plus gemcitabine (EG) vs. paclitaxel plus gemcitabine (PG) in patients with HER2-negative metastatic breast cancer (MBC) as first-line chemotherapy (KCSG BR13-11, NCT02263495).. Journal of Clinical Oncology, 2017, 35, 1082-1082.	0.8	1
98	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncology, The, 2016, 17, 577-589.	5.1	950
99	A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09. Supportive Care in Cancer, 2016, 24, 1709-1717.	1.0	19
100	First-in-human study of HM95573, a novel oral RAF inhibitor, in patients with solid tumors.. Journal of Clinical Oncology, 2016, 34, 2570-2570.	0.8	4
101	Phase II trial of nintedanib in patients with recurrent or metastatic salivary gland cancer: A multicenter phase II study.. Journal of Clinical Oncology, 2016, 34, 6090-6090.	0.8	3
102	A randomized, open label, phase II study comparing pemetrexed plus cisplatin followed by pemetrexed versus pemetrexed alone in EGFR mutant NSCLC patients who have failed first-line EGFR TKI: KCSG-LU12-13.. Journal of Clinical Oncology, 2016, 34, 9043-9043.	0.8	1
103	First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm+) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs).. Journal of Clinical Oncology, 2016, 34, 9046-9046.	0.8	11
104	BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: Efficacy and safety at the RP2D.. Journal of Clinical Oncology, 2016, 34, 9055-9055.	0.8	27
105	Open-label, multicenter, randomized phase III trial of pemetrexed/carboplatin doublet vs pemetrexed singlet in chemotherapy-naÃ¯ve elderly patients aged 70 or more with advanced non-squamous non-small cell lung cancer and good performance status.. Journal of Clinical Oncology, 2016, 34, 9081-9081.	0.8	1
106	A Prospective Multicenter Study Evaluating Secondary Adrenal Suppression After Antiemetic Dexamethasone Therapy in Cancer Patients Receiving Chemotherapy: A Korean South West Oncology Group Study. Oncologist, 2015, 20, 1432-1439.	1.9	21
107	Impact of the availability of active cytotoxic agents on the survival of patients with advanced gastric cancer. Oncology Letters, 2015, 10, 2481-2486.	0.8	1
108	Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncology, The, 2015, 16, 141-151.	5.1	1,369

#	Article	IF	Citations
109	Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncology, The, 2015, 16, 897-907.	5.1	389
110	Diagnostic performance of CD66c in lung adenocarcinoma-associated malignant pleural effusion: comparison with CEA, CA 19-9, and CYFRA 21-1. Pathology, 2015, 47, 123-129.	0.3	18
111	Therapeutic effect of anti CEACAM6 monoclonal antibody against lung adenocarcinoma by enhancing anoikis sensitivity. Biomaterials, 2015, 67, 32-41.	5.7	29
112	Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI).. Journal of Clinical Oncology, 2015, 33, 8084-8084.	0.8	28
113	A phase II, single-arm, efficacy and safety study of poziotinib (NOV120101) in Korean patients with advanced or metastatic lung adenocarcinoma who have acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors.. Journal of Clinical Oncology, 2015, 33, 8085-8085.	0.8	0
114	Prevalence and associated factors of anxiety and depression in patients with metastatic gastrointestinal cancer.. Journal of Clinical Oncology, 2015, 33, e20718-e20718.	0.8	0
115	Prospective multicenter study evaluating adrenal suppression after dexamethasone therapy as an antiemetic in cancer patients: a KSWOG (Korean South West Oncology Group) study.. Journal of Clinical Oncology, 2015, 33, 9605-9605.	0.8	0
116	E7080 (lenvatinib) in addition to best supportive care (BSC) versus BSC alone in third-line or greater nonsquamous, non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2014, 32, 8043-8043.	0.8	9
117	Multicenter phase II study of docetaxel and oxaliplatin combination in patients with locally advanced or metastatic biliary tract cancer.. Journal of Clinical Oncology, 2014, 32, e15150-e15150.	0.8	0
118	Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations. Journal of Clinical Oncology, 2013, 31, 3327-3334.	0.8	2,854
119	LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.. Journal of Clinical Oncology, 2012, 30, LBA7500-LBA7500.	0.8	74
120	LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.. Journal of Clinical Oncology, 2012, 30, LBA7500-LBA7500.	0.8	60
121	A Case of Superwarfarin Intoxication without a Definitive History of Brodifacoum Exposure. The Korean Journal of Hematology, 2009, 44, 53.	0.7	2